Patent intelligence · AU
AU 2013258031
Parenteral esmolol formulation
Parenteral esmolol formulation
Patent details — AU 2013258031
- Jurisdiction
- AU
- Status
- granted
- Grant date
- Nov 20, 2014
- Expiration
- Nov 15, 2034
- Applicant
- AOP ORPHAN PHARMACEUTICALS AG [AT]
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 08 A I, A61K 9/ 19 A I, A61K 31/ 24 A I
Quick answer
AU 2013258031 (Parenteral esmolol formulation) is held by AOP ORPHAN PHARMACEUTICALS AG [AT]. Status: granted. Granted Nov 20, 2014. Expires Nov 15, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AOP ORPHAN PHARMACEUTICALS AG [AT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 08 A I, A61K 9/ 19 A I, A61K 31/ 24 A I, A61K/3124, A61K/90019
More from AOP ORPHAN PHARMACEUTICALS AG [AT]
Related pharmaceutical patents in our USPTO index.
-
WO 2025172541
NOUVELLE COMPOSITION POUR L'AMÉLIORATION DE LA RECONSTITUTION DE LA MOELLE OSSEUSE ET DE LA RÉCUPÉRATION PÉRIPHÉRIQUE DES NUMÉRATIONS DE NEUTROPHILES ET DE PLAQUETTES
granted -
WO 2025153663
LANDIOLOL COMPLEXÉ ENCAPSULÉ OU DISSOUS DANS UNE MATRICE LIPOPHILE
granted -
LT 3544598
CANNABINOIDS FOR PROPHYLACTIC TREATMENT OF INVOLUNTARY WEIGHT LOSS
granted -
EP 2988750
VERWENDUNG VON LANDIOLOLHYDROCHLORID BEI DER LANGZEITBEHANDLUNG VON TACHYARRHYTHMIEN
granted -
AU 2009324043
Novel composition for treatment of essential thrombocythemia
granted -
AU 2008340179
Pharmaceutical composition for the parenteral administration of ultrashort-effective beta-adrenoreceptor antagonists
granted
Frequently asked questions
What is US patent 2013258031?
AU 2013258031 (Parenteral esmolol formulation) is held by AOP ORPHAN PHARMACEUTICALS AG [AT]. Status: granted. Granted Nov 20, 2014. Expires Nov 15, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns AU 2013258031?
AOP ORPHAN PHARMACEUTICALS AG [AT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does AU 2013258031 expire?
Our index shows an expiration date of Nov 15, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.